These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35152989)

  • 1. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
    Ding R; Chao CC; Gao Q
    Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
    Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
    Liu X; Zhao Y
    Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
    Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
    Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
    Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
    Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-Associated Viral Vectors for Homology-Directed Generation of CAR-T Cells.
    Moço PD; Aharony N; Kamen A
    Biotechnol J; 2020 Jan; 15(1):e1900286. PubMed ID: 31642193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.
    Pavlovic K; Carmona-Luque M; Corsi GI; Maldonado-Pérez N; Molina-Estevez FJ; Peralbo-Santaella E; Cortijo-Gutiérrez M; Justicia-Lirio P; Tristán-Manzano M; Ronco-Díaz V; Ballesteros-Ribelles A; Millán-López A; Heredia-Velázquez P; Fuster-García C; Cathomen T; Seemann SE; Gorodkin J; Martin F; Herrera C; Benabdellah K
    Front Immunol; 2024; 15():1401683. PubMed ID: 38868778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation.
    Porreca I; Blassberg R; Harbottle J; Joubert B; Mielczarek O; Stombaugh J; Hemphill K; Sumner J; Pazeraitis D; Touza JL; Francescatto M; Firth M; Selmi T; Collantes JC; Strezoska Z; Taylor B; Jin S; Wiggins CM; van Brabant Smith A; Lambourne JJ
    Mol Ther; 2024 Aug; 32(8):2692-2710. PubMed ID: 38937969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation-inducible CAR expression enables precise control over engineered CAR T cell function.
    Fraessle SP; Tschulik C; Effenberger M; Cletiu V; Gerget M; Schober K; Busch DH; Germeroth L; Stemberger C; Poltorak MP
    Commun Biol; 2023 Jun; 6(1):604. PubMed ID: 37277433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-step generation of modular CAR-T cells with AAV-Cpf1.
    Dai X; Park JJ; Du Y; Kim HR; Wang G; Errami Y; Chen S
    Nat Methods; 2019 Mar; 16(3):247-254. PubMed ID: 30804551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.